These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17724348)

  • 1. Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action.
    Markman M
    J Clin Oncol; 2007 Sep; 25(27):4168-70. PubMed ID: 17724348
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes in optimally debulked advanced ovarian cancer: a randomized clinical trial.
    Querleu D; Ferron G
    J Natl Cancer Inst; 2005 Nov; 97(21):1621; author reply 1621-3. PubMed ID: 16264186
    [No Abstract]   [Full Text] [Related]  

  • 3. Surgical management of recurrent ovarian cancer.
    Leitao MM; Chi DS
    Semin Oncol; 2009 Apr; 36(2):106-11. PubMed ID: 19332245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma.
    Salani R; Diaz-Montes T; Giuntoli RL; Bristow RE
    Ann Surg Oncol; 2007 Dec; 14(12):3552-7. PubMed ID: 17896149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma.
    Fagotti A; Ferrandina G; Fanfani F; Garganese G; Vizzielli G; Carone V; Salerno MG; Scambia G
    Am J Obstet Gynecol; 2008 Dec; 199(6):642.e1-6. PubMed ID: 18801470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies in the management of ovarian cancer--pros and cons for lymph node dissection in ovarian cancer.
    Camara O; Sehouli J
    Anticancer Res; 2009 Jul; 29(7):2837-43. PubMed ID: 19596971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer.
    Ledermann JA; Raja FA
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S104-15. PubMed ID: 21943964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer.
    Salani R; Axtell A; Gerardi M; Holschneider C; Bristow RE
    Gynecol Oncol; 2008 Feb; 108(2):271-5. PubMed ID: 18164380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen.
    Bristow RE
    Gynecol Oncol; 2009 Jan; 112(1):1-3. PubMed ID: 19100914
    [No Abstract]   [Full Text] [Related]  

  • 11. [The place of lumo-aortic and pelvic lymph node dissection in the treatment of ovarian cancer].
    Salet-Lizée D; Alsary S
    J Chir (Paris); 2008 Dec; 145 Spec no. 4():12S45-12S49. PubMed ID: 19194358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary cytoreduction in epithelial ovarian cancer recurrence: a perspective from a regional cancer center in India.
    Rema PN; Suchetha S; Mathew AP; Mathew A; Sebastian P
    J Reprod Med; 2009 Aug; 54(8):506-10. PubMed ID: 19769197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EORTC-GCG process quality indicators for ovarian cancer surgery.
    Verleye L; Ottevanger PB; van der Graaf W; Reed NS; Vergote I;
    Eur J Cancer; 2009 Mar; 45(4):517-26. PubMed ID: 19013789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The objectivity of reports describing the use of novel diagnostic tests in the management of ovarian cancer: a critique.
    Markman M
    Gynecol Oncol; 2007 Feb; 104(2):271-2. PubMed ID: 17258042
    [No Abstract]   [Full Text] [Related]  

  • 15. Colon resection for ovarian cancer: intraoperative decisions.
    Hoffman MS; Zervose E
    Gynecol Oncol; 2008 Nov; 111(2 Suppl):S56-65. PubMed ID: 18835022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
    Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
    Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.
    Kang S; Nam BH
    Ann Surg Oncol; 2009 Aug; 16(8):2315-20. PubMed ID: 19517192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience.
    Aletti GD; Dowdy SC; Gostout BS; Jones MB; Stanhope RC; Wilson TO; Podratz KC; Cliby WA
    J Am Coll Surg; 2009 Apr; 208(4):614-20. PubMed ID: 19476798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
    Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
    Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organisation and quality of primary surgical intervention for ovarian cancer in Denmark.
    Marx C; Bendixen A; Høgdall C; Ottosen C; Kehlet H; Ottesen B
    Acta Obstet Gynecol Scand; 2007; 86(12):1496-502. PubMed ID: 17851818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.